OUTLOOK THERAPEUTICS, INC. (OTLK) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
34/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinOTLK / S&P 671.84% / 15.20% |
LoseOTLK / S&P OTLK unavailable / 15.00% |
LoseOTLK / S&P 35.09% / 50.40% |
| 2026-Q11/3 |
LoseOTLK / S&P -86.96% / -4.33% |
LoseOTLK / S&P OTLK unavailable / 11.30% |
WinOTLK / S&P 28.57% / 27.70% |
| 2025-Q41/3 |
WinOTLK / S&P 49.06% / 2.65% |
LoseOTLK / S&P OTLK unavailable / 9.00% |
LoseOTLK / S&P -64.69% / 13.40% |
| 2025-Q30/3 |
LoseOTLK / S&P -33.75% / 8.12% |
LoseOTLK / S&P OTLK unavailable / 4.61% |
LoseOTLK / S&P -83.11% / 13.45% |
| 2025-Q21/3 |
WinOTLK / S&P 31.15% / 10.94% |
LoseOTLK / S&P OTLK unavailable / 4.83% |
LoseOTLK / S&P -94.70% / 10.63% |
| 2025-Q10/3 |
LoseOTLK / S&P -35.45% / -4.27% |
LoseOTLK / S&P OTLK unavailable / 4.98% |
LoseOTLK / S&P -92.07% / 10.57% |
| 2024-Q41/3 |
LoseOTLK / S&P -64.61% / 2.41% |
LoseOTLK / S&P OTLK unavailable / 5.25% |
WinOTLK / S&P 86.43% / 6.15% |
| 2024-Q31/3 |
LoseOTLK / S&P -27.64% / 5.89% |
LoseOTLK / S&P OTLK unavailable / 5.89% |
WinOTLK / S&P 181.25% / 6.11% |
| 2024-Q21/3 |
LoseOTLK / S&P -38.19% / 4.28% |
LoseOTLK / S&P OTLK unavailable / 5.38% |
WinOTLK / S&P 373.57% / 5.12% |
| 2024-Q12/3 |
WinOTLK / S&P 51.52% / 10.56% |
LoseOTLK / S&P OTLK unavailable / 5.71% |
WinOTLK / S&P 1450.00% / 5.59% |
| 2023-Q42/3 |
WinOTLK / S&P 78.28% / 11.69% |
LoseOTLK / S&P OTLK unavailable / 6.81% |
WinOTLK / S&P 1183.87% / 7.78% |
| 2023-Q31/3 |
LoseOTLK / S&P -87.30% / -3.27% |
LoseOTLK / S&P OTLK unavailable / 7.52% |
WinOTLK / S&P 932.26% / -5.03% |
| 2023-Q22/3 |
WinOTLK / S&P 59.63% / 8.74% |
LoseOTLK / S&P OTLK unavailable / 9.50% |
WinOTLK / S&P 587.88% / -8.57% |
| 2023-Q11/3 |
LoseOTLK / S&P 0.93% / 7.50% |
LoseOTLK / S&P OTLK unavailable / 10.77% |
WinOTLK / S&P 131.25% / -15.69% |
| 2022-Q41/3 |
LoseOTLK / S&P -11.48% / 7.56% |
LoseOTLK / S&P OTLK unavailable / 11.88% |
WinOTLK / S&P -3.12% / -17.99% |
| 2022-Q31/3 |
WinOTLK / S&P 19.61% / -4.88% |
LoseOTLK / S&P OTLK unavailable / 13.47% |
LoseOTLK / S&P -13.89% / -1.41% |
| 2022-Q21/3 |
LoseOTLK / S&P -42.70% / -16.10% |
LoseOTLK / S&P OTLK unavailable / 13.71% |
WinOTLK / S&P 26.92% / 11.04% |
| 2022-Q12/3 |
WinOTLK / S&P 30.88% / -4.60% |
LoseOTLK / S&P OTLK unavailable / 15.97% |
WinOTLK / S&P 45.45% / 42.23% |
| 2021-Q40/3 |
LoseOTLK / S&P -37.33% / 11.03% |
LoseOTLK / S&P OTLK unavailable / 15.00% |
LoseOTLK / S&P OTLK unavailable / 96.40% |
| 2021-Q30/3 |
LoseOTLK / S&P -12.85% / 0.58% |
LoseOTLK / S&P OTLK unavailable / 10.77% |
LoseOTLK / S&P OTLK unavailable / 69.42% |
| 2021-Q21/3 |
WinOTLK / S&P 10.67% / 8.55% |
LoseOTLK / S&P OTLK unavailable / 6.58% |
LoseOTLK / S&P OTLK unavailable / 51.81% |
| 2021-Q11/3 |
WinOTLK / S&P 73.08% / 6.17% |
LoseOTLK / S&P OTLK unavailable / -1.06% |
LoseOTLK / S&P OTLK unavailable / 7.39% |
| 2020-Q41/3 |
WinOTLK / S&P 80.56% / 12.15% |
LoseOTLK / S&P OTLK unavailable / -3.72% |
LoseOTLK / S&P OTLK unavailable / -33.42% |
| 2020-Q30/3 |
LoseOTLK / S&P -44.19% / 8.93% |
LoseOTLK / S&P OTLK unavailable / -2.04% |
LoseOTLK / S&P OTLK unavailable / -27.10% |
| 2020-Q21/3 |
WinOTLK / S&P 114.64% / 20.54% |
LoseOTLK / S&P OTLK unavailable / -0.46% |
LoseOTLK / S&P OTLK unavailable / -27.11% |
| 2020-Q11/3 |
WinOTLK / S&P 1.86% / -19.60% |
LoseOTLK / S&P OTLK unavailable / 3.47% |
LoseOTLK / S&P OTLK unavailable / -14.75% |
| 2019-Q40/3 |
LoseOTLK / S&P -60.40% / 9.07% |
LoseOTLK / S&P OTLK unavailable / 5.36% |
LoseOTLK / S&P OTLK unavailable / 2.99% |
| 2019-Q31/3 |
LoseOTLK / S&P -28.37% / 1.70% |
WinOTLK / S&P 163.84% / 5.02% |
LoseOTLK / S&P OTLK unavailable / 0.21% |
| 2019-Q20/3 |
LoseOTLK / S&P -71.89% / 4.30% |
LoseOTLK / S&P -41.27% / 6.64% |
LoseOTLK / S&P OTLK unavailable / 8.65% |
| 2019-Q11/3 |
WinOTLK / S&P 85.00% / 13.65% |
LoseOTLK / S&P -31.51% / 8.12% |
LoseOTLK / S&P OTLK unavailable / 14.29% |
| 2018-Q40/3 |
LoseOTLK / S&P -48.98% / -13.52% |
LoseOTLK / S&P -20.96% / 9.05% |
LoseOTLK / S&P OTLK unavailable / 18.23% |
| 2018-Q31/3 |
WinOTLK / S&P 15.98% / 7.71% |
LoseOTLK / S&P -18.99% / 10.21% |
LoseOTLK / S&P OTLK unavailable / 19.06% |
| 2018-Q21/3 |
LoseOTLK / S&P -5.06% / 3.43% |
WinOTLK / S&P 271.55% / 9.03% |
LoseOTLK / S&P OTLK unavailable / 14.46% |
| 2018-Q11/3 |
LoseOTLK / S&P -31.54% / -0.76% |
WinOTLK / S&P 197.54% / 7.68% |
LoseOTLK / S&P OTLK unavailable / 12.46% |
| 2017-Q41/3 |
LoseOTLK / S&P -5.11% / 6.64% |
WinOTLK / S&P 87.09% / 7.03% |
LoseOTLK / S&P OTLK unavailable / 13.82% |
| 2017-Q32/3 |
WinOTLK / S&P 37.00% / 4.48% |
WinOTLK / S&P 27.92% / 5.68% |
LoseOTLK / S&P OTLK unavailable / 17.57% |
| 2017-Q20/3 |
LoseOTLK / S&P -62.69% / 3.09% |
LoseOTLK / S&P -52.87% / 4.83% |
LoseOTLK / S&P OTLK unavailable / 17.74% |
| 2017-Q10/3 |
LoseOTLK / S&P -10.96% / 6.07% |
LoseOTLK / S&P -57.77% / 3.67% |
LoseOTLK / S&P OTLK unavailable / 13.32% |
| 2016-Q40/3 |
LoseOTLK / S&P -29.18% / 3.82% |
LoseOTLK / S&P -30.24% / 2.09% |
LoseOTLK / S&P OTLK unavailable / 7.05% |
| 2016-Q31/3 |
WinOTLK / S&P 25.00% / 3.85% |
LoseOTLK / S&P OTLK unavailable / 0.20% |
LoseOTLK / S&P OTLK unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | OTLK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -24.68% | 20.78% |
| Annualized return | -24.68% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | OTLK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.80% | 83.14% |
| Annualized return | -58.68% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | OTLK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.92% | 319.30% |
| Annualized return | -50.88% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |